The Role of Nitric Oxide in Cognition in Schizophrenia

• Status: Completed
• Trial end date: 2019-04-01
• Target enrollment: 0
• Participant gender: All

Summary

This study evaluates the role of the Nitric Oxide system in cognition in patients with schizophrenia. Participants will be randomised to 2 equal groups and receive either the Nitric Oxide donor molecule glyceryl trinitrate, or a placebo. Performance on several cognitive tasks will be assessed.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: King's College London
• Collaborator: South London and Maudsley NHS Foundation Trust
• Treatments: Nitric Oxide; Nitroglycerin

Criteria

Inclusion Criteria:

• 18-40 years of age

• Patients undergoing an acute psychotic episode (defined as score > 4 on question P1 of the PANSS positive subscale) requiring full-time hospitalisation according to clinical referral by the relevant mental health service

• Demonstrates capacity and willing to give informed consent

• Female participants willing to have a pregnancy test before treatment

• Currently unmedicated with antipsychotic medication

Exclusion Criteria:

• Major physical illness

• Prior history of intolerance to glyceryl trinitrate

• Homicidal or suicidal

• Pregnant or breast feeding